Munich, Bavaria, Germany · Hybrid
Executive Assistant (m/f/d) This is a full-time position based three days/week in Munich. Nuclidium AG is pioneering copper-based theranostics with its platform, developing a fully integrated diagnostic and therapeutic a…
Skills: Calendar Management, Travel Logistics, Board Meeting Coordination, Expense Management, Professional Communication
Sign up with Clera and we'll reach out the moment a role actually fits you — no more spraying applications into the void.
The Executive Assistant will manage complex calendars, travel logistics, and board-level operations for the CEO and senior leadership team. They will also handle administrative documentation, expense management, and act as the primary point of contact for internal and external stakeholders.
Candidates must have 3–5 years of experience as an executive assistant, preferably within the biotech or pharmaceutical sectors. Proficiency in English and German, along with strong organizational skills and experience with productivity software, is required.
Nuclidium AG is pioneering copper-based theranostics with its platform, developing a fully integrated diagnostic and therapeutic approach using Copper-61 (PET imaging) and Copper-67 (therapy). We are advancing a differentiated clinical pipeline targeting solid tumors with high unmet need while building a sustainable, global radionuclide production and manufacturing network.
We are seeking a highly organized Executive Assistant to support the CEO and senior leadership team. This role offers exposure to board-level operations, investors, and international stakeholders in a dynamic, fast-growing biotech.
\nKey Responsibilities
Setting a new standard in precision oncology
Nuclidium is setting a new standard in the precision oncology landscape by developing best-in-class copper-based radiopharmaceuticals that enable the highest accuracy and accessibility for targeted cancer treatment and diagnosis. Our flexible CuTraceTM platform combines copper radiometals with a variety of highly specific cancer-targeting molecules to rapidly develop novel therapeutic and diagnostic programs. The resulting product portfolio leverages the unique properties of copper to achieve an improved safety and efficacy profile with advantageous economics for hospitals and patients. Nuclidium’s differentiated “diagnostic to therapeutic” approach de-risks our development pathway. With innovation as our core, we overcome supply limitations in manufacturing and distribution, bringing greater flexibility to medical facilities. We are a diverse and interdisciplinary team focused on changing precision radio-oncology for the better to deliver a true benefit to cancer patients.
Offices: Bäumleingasse, Basel, BS 4051, CH · Munich, Munich, DE
Setting a new standard in precision oncology
Nuclidium is setting a new standard in the precision oncology landscape by developing best-in-class copper-based radiopharmaceuticals that enable the highest accuracy and accessibility for targeted cancer treatment and diagnosis. Our flexible CuTraceTM platform combines copper radiometals with a variety of highly specific cancer-targeting molecules to rapidly develop novel therapeutic and diagnostic programs. The resulting product portfolio leverages the unique properties of copper to achieve an improved safety and efficacy profile with advantageous economics for hospitals and patients. Nuclidium’s differentiated “diagnostic to therapeutic” approach de-risks our development pathway. With innovation as our core, we overcome supply limitations in manufacturing and distribution, bringing greater flexibility to medical facilities. We are a diverse and interdisciplinary team focused on changing precision radio-oncology for the better to deliver a true benefit to cancer patients.
Offices: Bäumleingasse, Basel, BS 4051, CH · Munich, Munich, DE
